The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy
Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without compensatory hyperinsulinemia, and hyperandrogenism a...
Saved in:
Main Authors: | Eduardo Spinedi, Daniel P. Cardinali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | International Journal of Endocrinology |
Online Access: | http://dx.doi.org/10.1155/2018/1349868 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Diagnosis and treatment of polycystic ovary syndrome
by: Ronelsys Martínez Martínez, et al.
Published: (2023-11-01) -
Expression of SET Protein in the Ovaries of Patients with Polycystic Ovary Syndrome
by: Xu Boqun, et al.
Published: (2013-01-01) -
Thiazolidinediones and Fertility in Polycystic Ovary Syndrome (PCOS)
by: Pascal Froment, et al.
Published: (2006-01-01) -
Polycystic Ovary Syndrome May Be an Autoimmune Disorder
by: Hifsa Mobeen, et al.
Published: (2016-01-01) -
Bariatric Surgery, Polycystic Ovary Syndrome, and Infertility
by: James Butterworth, et al.
Published: (2016-01-01)